SCHEMBL8201962

SCHEMBL8201962

CC(C)C[C@H](NC1CCN(c2ncc(C(=O)O)cn2)CC1)C(=O)OC1CCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.42
NPR3 P17342 1/20 0.41
DGAT2 Q96PD7 9/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
POLB P06746 1/20 0.39
MMP2 P08253 2/20 0.38
MMP9 P14780 2/20 0.38
ANPEP P15144 2/20 0.38
LTA4H P09960 1/20 0.38
LAP3 P28838 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3776460 0.90 HDAC6 (0.49) NPR3DGAT2HDAC3HDAC4HDAC1
SCHEMBL3776456 0.90 HDAC6 (0.49) NPR3DGAT2HDAC3HDAC4HDAC1
SCHEMBL8194150 0.89 DGAT2 (0.40) HRH3NPR3DGAT2HDAC3HDAC4
SCHEMBL15906848 0.89 HRH3 (0.39) HRH3NPR3DGAT2HDAC3HDAC4
SCHEMBL8205770 0.86 DGAT2 (0.43) HRH3NPR3DGAT2HDAC3HDAC4
SCHEMBL8205837 0.85 USP2 (0.46) HRH3NPR3MMP2MMP9ANPEP
SCHEMBL8202007 0.84 DGAT2 (0.37) HRH3NPR3DGAT2HDAC3HDAC4
SCHEMBL13061241 0.79 HDAC6 (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL13061464 0.79 HDAC6 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL16517896 0.79 HDAC6 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962825-B2 Hydroxamates as inhibitors of histone deacetylase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-02-24 US disclosed
US-8962825-B2 Hydroxamates as inhibitors of histone deacetylase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-02-24 US disclosed
EP-2077999-B1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE CHROMA THERAPEUTICS LTD (GB) 2014-07-30 EP disclosed
US-20100317678-A1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE CHROMA THERAPEUTICS LTD. (GB) 2010-12-16 US disclosed
US-20100317678-A1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE CHROMA THERAPEUTICS LTD. (GB) 2010-12-16 US disclosed
WO-2008053131-A1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE CHROMA THERAPEUTICS LTD. (GB) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317678-A1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE H1-2, HDAC1, H1-0 HRH3 44/4885NPR3 3648/4885DGAT2 4057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.